Carbohydrate-based Antibacterial Glycomedicine Development

Carbohydrate-based Antibacterial Glycomedicine Development

CD BioGlyco is a world-leading independent biotechnology company, focusing on high-quality innovative services related to glycobiology. CD BioGlyco has professional glycomedicine development teams with multiple world-leading technologies to help customers comprehensively promote the development of carbohydrate-based antibacterial glycomedicine.

Bacteria and Carbohydrate-based Antibiotics

Bacteria are closely associated with human health down the ages. There have been many bacteria incurred pandemics throughout history, including the bubonic plague caused by Yersinia pestis, tuberculosis caused by Tubercle bacilli, cholera caused by Vibrio cholera, and anthrax caused by Bacillus anthracis. Even today, bacterial infections remain severe threatens to human health and life.

The protein synthesis machines are important targets of carbohydrate-based antibiotics. One important factor is that the 70S ribosome of bacteria is made up of a 30S small subunit and a 50S large subunit, which is significantly different from the 80S ribosome of eukaryotic cells. Thus, carbohydrate-conjugated macrolide antibiotics and aminoglycoside antibiotics (AGs) can selectively disrupt the ribosomal functions required for the bacterial protein synthesis without affecting protein synthesis in eukaryotic cells. Another unique structural feature of bacteria is their cell wall, which are mainly composed of peptidoglycans and glycolipids. In order to produce these glycans, bacteria maintain sophisticated and distinctive biosynthesis systems, which are absent in eukaryotes. This vital biosynthesis process of bacteria could be exploited by antibiotics to suppress bacterial infections. However, with the widespread use of antibiotics, antimicrobial resistance (AMR) has become a global health threat. Discovery of new antibiotic drugs is important to this global challenge.

Fig 1. Mechanisms of bacterial drug resistance.Fig.1 Mechanisms of bacterial drug resistance. (Ritter & Wong,2001)

Carbohydrate-based Antibacterial Glycomedicine Development Services

As a leading platform provider in carbohydrate-based glycomedicine development, CD BioGlyco has various systematic services for the Synthesis of carbohydrate-based antibiotics, including four important classes of carbohydrate-containing antibiotics – aminoglycosides, nucleosides, macrolides and glycopeptides. Besides, we offers services for Antibacterial activity assay. The quantitative determination of antibiotics, the detection of bacteria, screening of compounds with antibacterial activity and antibiotic susceptibility testing. The methods include but are not limited to:

  • Chromatographic.
  • Electrophoresis.
  • Diode array.
  • Enzyme immunosorbent assay.
  • The culture-based method.

Advantages of Us

  • Cutting-edge technology and professional research team.
  • High selectivity and rapid detection.
  • Outstanding scientists specialize in glycomedicine development.

With a first-class experimental platform and professional research teams, CD BioGlyco is committed to ensuring that every service provides the highest level of satisfaction. Our professional research teams provide customers with high-quality carbohydrate-based antibacterial glycomedicine development services according to their needs. If you are interested in our services, please contact us to obtain more information.


  1. Ritter, T. K.; Wong, C. H. Carbohydrate-based antibiotics: a new approach to tackling the problem of resistance. Angewandte Chemie International Edition. 2001, 40(19): 3508-3533.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.